AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer. The importance of biosimilars only continues ...

In the space of four days, the number of FDA-approved therapies for ultra-rare genetic disorder Niemann-Pick disease has gone from zero to two, transforming the prospects for patients. IntraBio's ...